CVS Health experienced significant upward price movement and heightened intraday volatility, driven by a major strategic announcement targeting the high-growth weight loss and diabetes medication market. Specifically, the company unveiled a comprehensive support framework for GLP-1 medications across its extensive network of retail pharmacies and MinuteClinic locations. This proactive business expansion addresses a critical area of consumer demand, immediately capturing the attention of both institutional and retail investors.

The cornerstone of CVS’s announcement is the launch of a new virtual weight management consultation service through MinuteClinic for an affordable flat fee, providing self-pay patients with streamlined access to…